By Dr Lynn Butler The barriers to establishing an equitable partnership between biotechs and big pharma are high and many partnerships, once established, do not deliver the tangible and non-tangible value expected by the licensor. This article addresses how to develop and implement a partnering strategy that will deliver attractive value, avoid the erosion of […]